Publications by authors named "Marjolein Bruin-Weller"
Background: Lebrikizumab demonstrated statistically significant improvements in patients with moderate-to-severe atopic dermatitis at week 16 with a durable response up to week 52.
Objective: To investigate the efficacy of lebrikizumab-treated patients at 52 weeks who did not achieve the ADvocate1 and ADvocate2 protocol-defined response criteria (≥75% improvement in the Eczema Area and Severity Index [EASI 75] or Investigator Global Assessment [IGA] 0/1 with ≥2-point improvement without rescue medication) after 16 weeks.
Methods: This analysis includes observed data for patients who received lebrikizumab every 2 weeks during the induction period, did not achieve the protocol-defined response, and subsequently received open-label lebrikizumab treatment.
Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).
View Article and Find Full Text PDFIntroduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.
View Article and Find Full Text PDFArticle Synopsis
- Atopic dermatitis (AD) significantly impacts patients' quality of life, and the Atopic Dermatitis Control Tool (ADCT) is used to measure how well it's being managed in adults.
- A study involving 863 participants revealed that 59% had controlled AD, while those with uncontrolled AD had higher symptom severity and were more likely to be using topical treatments only.
- The findings suggest that shifting treatment strategies from topical to systemic therapies might benefit patients struggling with uncontrolled AD symptoms.
Article Synopsis
- - The study evaluates the effectiveness and longevity of treatments (dupilumab, methotrexate, and cyclosporine A) for pediatric patients aged 2-17 with severe atopic dermatitis across five centers in the Netherlands from 2013-2023.
- - Out of 502 treatment episodes analyzed, dupilumab showed the highest drug survival rates over three years (84.1% at one year, 72.3% at two, and 62.0% at three), compared to significantly lower rates for methotrexate and cyclosporine A.
- - The main reason for discontinuing treatment was ineffectiveness, especially noted with cyclosporine A, while factors like treatment
Article Synopsis
- Biologics and small-molecule therapies have improved the treatment landscape for atopic dermatitis, but older systemic treatments are still in use.
- The PEDIatric STudy in Atopic Dermatitis is a 10-year observational study tracking the effectiveness and safety of dupilumab, cyclosporine, and methotrexate in children under 12 with moderate-to-severe atopic dermatitis, with interim results available after 2 years.
- Results show that dupilumab led to better improvements in skin severity, itching, and fewer discontinuations or adverse effects compared to methotrexate and cyclosporine.
Article Synopsis
- Atopic dermatitis is a chronic skin condition that causes symptoms like itching and sleep disturbances, impacting quality of life, and lebrikizumab, an interleukin-13 inhibitor, is approved for treating moderate-to-severe cases in various countries.
- In two phase 3 studies (ADvocate1 and ADvocate2), adults and adolescents with moderate-to-severe atopic dermatitis received either lebrikizumab or a placebo every two weeks for 16 weeks to assess treatment efficacy.
- Results demonstrated significant improvements in skin severity, itching, sleep loss, and quality of life metrics for patients taking lebrikizumab compared to those on placebo, particularly notable after 16 weeks of treatment.
Article Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
Article Synopsis
- - The study focused on atopic dermatitis (AD) and evaluated how much time patients spent with clear skin and minimal itch while being treated with upadacitinib compared to a placebo and dupilumab.
- - Researchers analyzed data from three phase 3 studies involving nearly 2,400 patients, with treatments lasting from 16 to 24 weeks and assessed using established skin severity and itch scales.
- - Results showed that patients on upadacitinib experienced significantly more days with better skin conditions and reduced itching compared to those on placebo or dupilumab.
Article Synopsis
- - Abrocitinib is an FDA-approved oral medication for treating moderate-to-severe atopic dermatitis (AD) in both adults and adolescents, and it has proven to be effective in clinical trials with a good safety profile over time.
- - A 200-mg daily dose of abrocitinib offers quicker relief from itching and better skin improvement compared to dupilumab, but monitoring for potential side effects is crucial due to risks associated with all oral JAK inhibitors.
- - The use of abrocitinib is appropriate for qualified patients needing systemic AD therapy, though caution is advised for specific populations such as older adults and those with certain health risks, with a recommendation to start with a lower 100-mg dose in
Article Synopsis
- Atopic dermatitis (AD) is commonly linked with asthma and allergic rhinitis (AR), and while dupilumab is an effective treatment for AD in children, its impact on these related conditions hasn't been well-studied.
- In this study, 84 pediatric patients receiving dupilumab were examined, revealing that 59.5% had asthma and 85.7% had AR at baseline, with various tests conducted to assess their health status.
- Results showed significant improvements after one year of treatment, including decreased levels of FeNO (indicating lowered airway inflammation) and reduced aeroallergen-specific IgE levels in patients with asthma and/or AR.
A treat-to-target approach was recently developed to guide systemic treatment for adults with atopic dermatitis (AD). Recommendations outlined criteria for a 3-month initial acceptable treatment target and a 6-month optimal target, evaluated using global assessment of patient-reported disease severity, as well as Eczema Area and Severity Index, itch assessed on an 11-point numerical rating scale, Dermatology Life Quality Index, or Patient-Oriented Eczema Measure. Achievement of these targets with once-daily upadacitinib (15 mg and 30 mg) monotherapy was evaluated using integrated adult data from the Measure Up 1 and 2 phase 3 studies.
View Article and Find Full Text PDFArticle Synopsis
- Atopic dermatitis (AD) is a skin condition that can be difficult to treat in certain body areas; this study focused on how lebrikizumab impacts AD severity across different regions.
- In two clinical trials, lebrikizumab was administered every two weeks, and patients showed significant improvement in the Eczema Area and Severity Index (EASI) after 16 weeks compared to those given a placebo.
- Results indicated that lebrikizumab led to rapid improvements in AD symptoms, with significant advancements observable as early as week 2, particularly benefiting all body regions and clinical signs measured.
Article Synopsis
- Atopic dermatitis (AD) significantly impacts quality of life due to intense itching and other symptoms; this study investigates the effects of the oral medication upadacitinib on patients with moderate-to-severe AD over 16 weeks.
- The analysis included data from 1,683 patients in clinical trials, showing that those taking upadacitinib experienced notable improvements in itching and other quality of life indicators compared to those on a placebo, starting as early as one week and continuing through the study period.
- Results indicated that patients on upadacitinib reported better outcomes in areas like skin pain, sleep, daily activities, emotional well-being, and overall treatment satisfaction, suggesting this medication could be an effective option for managing AD
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
J Am Acad Dermatol
August 2024
Article Synopsis
- A study evaluated the effectiveness and safety of dupilumab for treating moderate-to-severe atopic dermatitis (AD) over a long-term period of up to 5 years, emphasizing patient-reported outcomes.
- Data from 1223 patients (1108 adults and 115 children) showed improved quality of life measures and work impairment in both groups after at least one year of treatment.
- Despite the treatment's favorable safety profile, including a 66.8% reporting rate of adverse events (most commonly conjunctivitis), there were significant amounts of missing data in reported outcomes, particularly in children.
Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment with these new targeted treatments, more insight into the occurrence and pathomechanism of OSD in moderate-to-severe AD patients is needed. Therefore, this review's first part highlights that most patients with moderate-to-severe AD already have characteristics of OSD before starting targeted treatment.
View Article and Find Full Text PDFArticle Synopsis
- * Out of 103 patients, significant improvements were observed over 28 weeks, with high rates of reduction in eczema severity and itching.
- * While some patients discontinued due to ineffectiveness or adverse events (mainly nausea), abrocitinib showed effectiveness for those who previously did not respond to other treatments like dupilumab or upadacitinib.
Article Synopsis
- Pathogenic variants in the filaggrin (FLG) gene are linked to a higher risk of developing atopic dermatitis (AD), prompting this study to explore how these variants affect dupilumab treatment outcomes.
- A total of 285 adult patients with AD were assessed for FLG variants and treatment effectiveness using various measures at the start and after 16 and 52 weeks of treatment.
- The findings revealed that dupilumab's effectiveness was similar for patients with and without pathogenic FLG variants, but those with biallelic variants reported worse skin dryness and flaking over time compared to others.